$AKTX
Akari Therapeutics Plc

2015 Q2 Form 10-Q Financial Statement

#000114420415048274 Filed on August 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q4 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.314M $30.00K $790.0K
YoY Change 66.33%
% of Gross Profit
Research & Development $142.0K $1.080M $1.540M
YoY Change -90.78%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.456M $1.110M $2.330M
YoY Change -37.51%
Operating Profit -$1.456M -$2.330M
YoY Change -37.51%
Interest Expense -$20.00K -$10.00K -$160.0K
YoY Change -87.5%
% of Operating Profit
Other Income/Expense, Net -$215.0K $0.00 $101.0K
YoY Change -312.87%
Pretax Income -$1.671M -$1.110M -$2.229M
YoY Change -25.03%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.671M -$1.110M -$2.229M
YoY Change -25.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.679K -$9.013K $11.57K
COMMON SHARES
Basic Shares Outstanding 55.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2014 Q4 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.720M
YoY Change
Cash & Equivalents $2.718M $3.327M $11.36M
Short-Term Investments
Other Short-Term Assets $140.0K
YoY Change
Inventory
Prepaid Expenses
Receivables $60.00K
Other Receivables $0.00
Total Short-Term Assets $2.920M $3.335M
YoY Change -57.42%
LONG-TERM ASSETS
Property, Plant & Equipment $40.00K $0.00
YoY Change
Goodwill
YoY Change
Intangibles $59.42K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $40.00K $59.42K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.920M $3.335M
Total Long-Term Assets $40.00K $59.42K
Total Assets $2.960M $3.395M
YoY Change -56.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $630.0K $555.5K
YoY Change
Accrued Expenses $43.00K
YoY Change -89.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $960.0K $1.171M
YoY Change -4.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $43.00K $33.00K
YoY Change
Total Long-Term Liabilities $43.00K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $960.0K $1.171M
Total Long-Term Liabilities $43.00K $0.00
Total Liabilities $1.003M $1.171M
YoY Change -41.95%
SHAREHOLDERS EQUITY
Retained Earnings -$11.48M
YoY Change -44.12%
Common Stock $13.66M
YoY Change -48.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $970.0K $2.223M $10.42M
YoY Change
Total Liabilities & Shareholders Equity $2.960M $3.395M
YoY Change -56.66%

Cashflow Statement

Concept 2015 Q2 2014 Q4 2014 Q2
OPERATING ACTIVITIES
Net Income -$1.671M -$1.110M -$2.229M
YoY Change -25.03%
Depreciation, Depletion And Amortization $10.00K $0.00 $0.00
YoY Change
Cash From Operating Activities -$1.510M -$670.0K -$2.330M
YoY Change -35.19%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$140.0K
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 -$140.0K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.900M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.510M -670.0K -2.330M
Cash From Investing Activities 0.000 0.000 -140.0K
Cash From Financing Activities 0.000 3.900M 0.000
Net Change In Cash -1.510M 3.230M -2.470M
YoY Change -38.87%
FREE CASH FLOW
Cash From Operating Activities -$1.510M -$670.0K -$2.330M
Capital Expenditures $0.00
Free Cash Flow -$670.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Other Restricted Assets Current
OtherRestrictedAssetsCurrent
142000 USD
CY2014Q4 us-gaap Other Restricted Assets Current
OtherRestrictedAssetsCurrent
142000 USD
CY2015Q2 cltx Accounts Receivable And Prepaid Expenses Net Current
AccountsReceivableAndPrepaidExpensesNetCurrent
60000 USD
CY2014Q4 cltx Accounts Receivable And Prepaid Expenses Net Current
AccountsReceivableAndPrepaidExpensesNetCurrent
73000 USD
CY2015Q2 us-gaap Assets Current
AssetsCurrent
2920000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
6431000 USD
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49000 USD
CY2015Q2 us-gaap Assets
Assets
2960000 USD
CY2014Q4 us-gaap Assets
Assets
6480000 USD
CY2015Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
629000 USD
CY2014Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1003000 USD
CY2015Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
331000 USD
CY2014Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
356000 USD
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
960000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1359000 USD
CY2015Q2 cltx Liability Related To Stock Options And Warrants
LiabilityRelatedToStockOptionsAndWarrants
984000 USD
CY2014Q4 cltx Liability Related To Stock Options And Warrants
LiabilityRelatedToStockOptionsAndWarrants
235000 USD
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33000 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1540000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
142000 USD
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
790000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2718000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6216000 USD
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55636283 shares
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1314000 USD
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2330000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1456000 USD
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
101000 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-215000 USD
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-1671000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2229000 USD
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1671000 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2229000 USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55636283 shares
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55636283 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2340000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1693000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1873000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2105000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4213000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3798000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
244000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-750000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3988000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3969000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4548000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3969000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-560000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52571643 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55636283 shares
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
108000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
5814000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8219000 USD
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
56000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
295000 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
10415000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
351000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
108000 USD
us-gaap Depreciation
Depreciation
0 USD
cltx Increase Decrease In Values Of Deferred Shares And Liability Related To Stock Options And Warrants
IncreaseDecreaseInValuesOfDeferredSharesAndLiabilityRelatedToStockOptionsAndWarrants
259000 USD
cltx Increase Decrease In Values Of Deferred Shares And Liability Related To Stock Options And Warrants
IncreaseDecreaseInValuesOfDeferredSharesAndLiabilityRelatedToStockOptionsAndWarrants
-749000 USD
cltx Increase Decrease In Accounts Receivables And Prepaid Expense
IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense
719000 USD
cltx Increase Decrease In Accounts Receivables And Prepaid Expense
IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense
-13000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
619000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-374000 USD
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-399000 USD
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-25000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4376000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3498000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8219000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3701000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3498000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7657000 USD
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55636283 shares
CY2007Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1365000 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11358000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
10000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-142000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-749000 USD
CY2015Q2 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
984000 USD
CY2013Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
787000 USD
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
552000 USD
CY2014Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
235000 USD
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
147000 USD
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
297000 USD
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
313000 USD
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
330000 USD
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
225000 USD
CY2015Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2308000 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2903227 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2703227 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.42
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.47
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
200000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2703227 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1753227 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.47
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2015Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
CY2014Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1312000 USD
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55636283 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55636283 shares
CY2015Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1671000 USD
CY2014Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2229000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3988000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3969000 USD
CY2014Q2 cltx Warrants Expired During Period
WarrantsExpiredDuringPeriod
562500 shares
CY2015Q2 cltx Warrants Stock Reserved For Future Issuance Under Price Protection
WarrantsStockReservedForFutureIssuanceUnderPriceProtection
729450 shares
CY2014 cltx Warrants Granted Value
WarrantsGrantedValue
235000 USD
cltx Warrants Granted Value
WarrantsGrantedValue
984000 USD
CY2015Q2 cltx Share Based Compensation Arrangement By Share Based Payment Award Options And Warrants Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsOutstandingNumber
631970 shares
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
142000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
108000 USD
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
172000 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
15333300 shares
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8219000 USD
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
981000 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56000 USD
CY2014Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.60
CY2014Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.60
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Share Price
SharePrice
0.01
CY2014Q4 us-gaap Share Price
SharePrice
0.01
CY2015Q2 cltx Common Stock Capital Shares Reserved For Future Issuance Under Most Favoured Nations Terms
CommonStockCapitalSharesReservedForFutureIssuanceUnderMostFavouredNationsTerms
5659717 shares
CY2015Q2 cltx Common Stock Capital Shares Reserved For Future Issuance Under Price Protection
CommonStockCapitalSharesReservedForFutureIssuanceUnderPriceProtection
5089544 shares

Files In Submission

Name View Source Status
0001144204-15-048274-index-headers.html Edgar Link pending
0001144204-15-048274-index.html Edgar Link pending
0001144204-15-048274.txt Edgar Link pending
0001144204-15-048274-xbrl.zip Edgar Link pending
cltx-20150630.xml Edgar Link completed
cltx-20150630.xsd Edgar Link pending
cltx-20150630_cal.xml Edgar Link unprocessable
cltx-20150630_def.xml Edgar Link unprocessable
cltx-20150630_lab.xml Edgar Link unprocessable
cltx-20150630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v417157_10q.htm Edgar Link pending
v417157_ex31-1.htm Edgar Link pending
v417157_ex31-2.htm Edgar Link pending
v417157_ex32-1.htm Edgar Link pending